This includes DNMT inhibitors such as azacitidine, approved for the treatment of myelodysplastic syndrome and acute myeloid leukemia, as well as HDAC inhibitors such as panobinostat, a third-line treatment for multiple myeloma [186]. Here, HDAC9 is linked to plasma cell myeloma.